Michael A. Jakupec

NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

Robert Trondl, Petra Heffeter, Christian R. Kowol et al. · Chemical Science · 2014 · 652 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Tumor Biology +16

Redox behavior of tumor-inhibiting ruthenium(<scp>iii</scp>) complexes and effects of physiological reductants on their binding to GMP

Petra Schluga, Christian G. Hartinger, Alexander Egger et al. · Dalton Transactions · 2006 · 215 citations · Full text

Structure−Activity Relationships for NAMI-A-type Complexes (HL)[<i>trans</i>-RuCl₄L(<i>S</i>-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4-triazole, and 1-Methyl-1,2,4-triazole):  Aquation, Redox Properties, Protein Binding, and Antiproliferative Activity

Michael Groessl, Erwin Reisner, Christian G. Hartinger et al. · Journal of Medicinal Chemistry · 2007 · 212 citations

Nami-a-type Complexes, Chemistry, Pharmaceutical Chemistry +16

Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy

M. Pongratz, Petra Schluga, Michael A. Jakupec et al. · Journal of Analytical Atomic Spectrometry · 2004 · 203 citations

Molecular Biology, Chemical Biology, Cancer Biology +25

Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells

Susanne Kapitza, M. Pongratz, Michael A. Jakupec et al. · Journal of Cancer Research and Clinical Oncology · 2004 · 197 citations · Full text

Tumor Biology, Inorganic Chemistry, Medicine +9